Modality
siRNA
MOA
USP1i
Target
C5
Pathway
NF-κB
AsthmaMCLProstate Ca
Development Pipeline
Preclinical
~Nov 2014
→ ~Feb 2016
Phase 1
~May 2016
→ ~Aug 2017
Phase 2
Nov 2017
→ May 2030
Phase 2Current
NCT05163134
41 pts·Asthma
2017-11→2030-05·Terminated
41 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-124.1y awayPh3 Readout· Asthma
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Termina…
Catalysts
Ph3 Readout
2030-05-12 · 4.1y away
Asthma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05163134 | Phase 2/3 | Asthma | Terminated | 41 | Biomarker |
Competitors (10)